{
  "abstract": "Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improve glycaemic control,1 promote weight loss,2 delay progression of kidney disease,3 and reduce major adverse cardiovascular events (including myocardial infarction and stroke)4–6 in people with type 2 diabetes mellitus. The expanding indications of GLP-1RAs—including for individuals with obesity but who do not have diabetes—have driven rapid global uptake.7 However, discontinuation is common, with studies reporting that up to half of patients stop treatment with a GLP-1RA within the first year.8 9 Although previous evidence suggests that interruption or discontinuation of GLP-1RAs may diminish or reverse their beneficial cardiometabolic effects,10 the impact on major adverse cardiovascular events has remained uncertain.",
  "authors": [
    {
      "affiliations": [
        "Hull York Medical School, York, England, UK",
        "Academic Cardiovascular Unit, James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, UK",
        "Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire, UK",
        "Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK"
      ],
      "name": "Jonathan A Batty"
    },
    {
      "affiliations": [
        "Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire, UK",
        "Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK"
      ],
      "name": "Tamara del Toro"
    },
    {
      "affiliations": [
        "Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire, UK",
        "Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK"
      ],
      "name": "Marlous Hall"
    }
  ],
  "title": "Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists",
  "uid": "befd29b1-3275-5f0e-af35-de3b41747027"
}